Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Abt 263
2. Abt-263
3. Abt263
1. 923564-51-6
2. Abt-263
3. Abt 263
4. Abt263
5. Abt-263 (navitoclax)
6. Navitoclax (abt-263)
7. Unii-xkj5vvk2wd
8. Xkj5vvk2wd
9. A-855071.0
10. Chembl443684
11. (r)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-n-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
12. 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-n-[[4-[[(1r)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
13. 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
14. (r)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-n-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)p
15. (r)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-n-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide
16. 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({4-({(1r)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
17. 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-[(4-{[(2r)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
18. Navitoclax [usan]
19. Navitoclax [usan:inn]
20. Navitoclaxum
21. C47h55clf3n5o6s3
22. 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((4-(((2r)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
23. Abt-263,navitoclax
24. Navitoclax [mi]
25. Abt-263 In Bulk
26. Navitoclax, Abt-263
27. Navitoclax; Abt-263
28. Navitoclax [inn]
29. Navitoclax [jan]
30. Navitoclax (usan/inn)
31. Abt-263 - Navitoclax
32. Navitoclax [who-dd]
33. Mls006011021
34. Schembl522847
35. Gtpl8319
36. Dtxsid2042640
37. Chebi:94128
38. Ex-a055
39. Chebi:131174
40. Bdbm50270877
41. Mfcd12756219
42. Nsc759659
43. S1001
44. Akos015896297
45. Zinc150338726
46. Db12340
47. Nsc-759659
48. Rg-7433
49. Ncgc00188344-01
50. Ncgc00188344-02
51. Ncgc00188344-03
52. Ncgc00188344-05
53. Ncgc00188344-08
54. 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-n-[[4-[[(1r)-3-(4-mo
55. 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(1r)-3-morpholino-1-(phenylsulfanylmethyl)propyl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-benzamide
56. Ac-31055
57. As-16690
58. Hy-10087
59. Smr004702817
60. 4-[4-[[2-(4-chlorophenyl)-5,5-dimet
61. Sw218055-2
62. D09935
63. 564a516
64. J-519525
65. Brd-k82746043-001-01-1
66. Brd-k82746043-001-02-9
67. Brd-k82746043-001-03-7
68. Brd-k82746043-001-04-5
69. Q18002993
70. (r)-4-(4-((4-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-n-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
71. 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((4-(((1r)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
72. 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-(4-(((2r)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl)amino)-3-(trifluoromethanesulfonyl)benzenesulfonyl)benzamide
73. 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-n-[[4-[[(1r)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide;abt 263;benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dime
74. 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-n-[(4-{[(2r)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
75. Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1- Piperazinyl)-n-((4-(((1r)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-
76. Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-
77. N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethyl-cyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-4-((r)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonyl-benzenesulfonamide
Molecular Weight | 974.6 g/mol |
---|---|
Molecular Formula | C47H55ClF3N5O6S3 |
XLogP3 | 9.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 16 |
Exact Mass | 973.2955102 g/mol |
Monoisotopic Mass | 973.2955102 g/mol |
Topological Polar Surface Area | 170 Ų |
Heavy Atom Count | 65 |
Formal Charge | 0 |
Complexity | 1800 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of myelofibrosis
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Navitoclax targets the Bcl-2 family of proteins, the major negative regulators of apoptosis. The Bcl-2 proteins, including Bcl-2, Bcl-xL, and Bcl-w, work by binding to two other groups of proteins-the executioners (Bax, Bak) that actually start the destruction pathway, and the sentinel proteins. Cancer cells frequently overexpress the Bcl-2-like proteins, and thus, when they sustain DNA damage-from radiation, for example-they continue growing. Preventing the Bcl-2-like proteins from binding to the executioners might be able to trigger cell death in the tumor.
ABOUT THIS PAGE
A Navitoclax manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Navitoclax, including repackagers and relabelers. The FDA regulates Navitoclax manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Navitoclax API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Navitoclax supplier is an individual or a company that provides Navitoclax active pharmaceutical ingredient (API) or Navitoclax finished formulations upon request. The Navitoclax suppliers may include Navitoclax API manufacturers, exporters, distributors and traders.
Navitoclax Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Navitoclax GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Navitoclax GMP manufacturer or Navitoclax GMP API supplier for your needs.
A Navitoclax CoA (Certificate of Analysis) is a formal document that attests to Navitoclax's compliance with Navitoclax specifications and serves as a tool for batch-level quality control.
Navitoclax CoA mostly includes findings from lab analyses of a specific batch. For each Navitoclax CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Navitoclax may be tested according to a variety of international standards, such as European Pharmacopoeia (Navitoclax EP), Navitoclax JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Navitoclax USP).
LOOKING FOR A SUPPLIER?